Contact Us: 01282 426380
KM Financial Solutions | UPDATE 1-U.S. committee recommends GSK shingles vaccine over Merck rival
2397
post-template-default,single,single-post,postid-2397,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

UPDATE 1-U.S. committee recommends GSK shingles vaccine over Merck rival

24 Oct UPDATE 1-U.S. committee recommends GSK shingles vaccine over Merck rival

Posted at 17:25h in News by
0 Likes
LONDON, Oct 25 (Reuters) – The committee responsible for
U.S. vaccination schedules has given a preferential
recommendation to GlaxoSmithKline’s newly approved
shingles vaccine Shingrix over Merck & Co’s established
product Zostavax.

No Comments

Post A Comment